Assistant Medical

SUMMARY

Accomplished, energetic, Associate Research Scientist II from a global biopharmaceutical company has significant experience in cell biology, tissue culture, and molecular biology. Double and triple drug combination studies performed in vitro resulting in 2 patents to date and multiple inhibitors brought to clinic.

MAJOR ACCOMPLISHMENTS

Double and triple drug combination studies resulting in 2 patents to date and the major driver for multiple HCV inhibitors to clinic. Drugs performing well in clinic to date.

Designed and developed cellular assays to address and follow HCV toxicity enhancing the understanding of compound SAR.

Through testing site specific mutations, assisted in profiling compound resistance.

Enhanced the development of a potent Respiratory Syncytial Virus inhibitor through cellular and protein assays. Drug is waiting for First in Man studies.

Studied and confirmed the inhibition of Locbucavir against Human Cytomegalovirus through cellular assays.

Developed and maintained a successful Media Preparation Laboratory supervising three individuals.

SKILLS AND TECHNIQUES

Tissue culture. Expansion, maintenance and freezing of cell lines. Performing combination studies for the treatment of HCV. Making and testing primary cell lines, both rat lung and liver. Make compound resistant cell lines by compound pressure or molecular biology, maintenance, testing for activity. Harvesting RNA from cell lines. Making RNA transcripts. Performing transfections, transformations, mini, midi and maxi preps, sequencing, single cycle labeling, viral plaquing, working with HCV and Dengue replicon, Interferon Alpha, Ribavirin, Interferon Lambda,

Performing FRET, Luciferase, and Ribogreen (RNA binding) assays including set up, titrations, harvest, and data analysis.

Molecular biology: including isolating DNA, pcr, transformations, cloning, enzyme digestions, and electrophoresis. Can make RNA transcripts.

Protein expression, purification, SDS page, immunoprecipitation, comfortable with radioactivity.

Proficient in use of Microsoft Calendar, Word, Excel, xlfit, and Powerpoint. Used SAS based combination therapy program and MacSynergy. Abase, Toolset, Guava cytometer, microplate readers (Gemini and Cytofluor), Topcount, centrifuges, Qiagen kits, electrophoreses, western analysis, Storm densitometer (Imagequant software), spectrophotometer, Nanodrop, fluorescent microscopy.

PROFESSIONAL EXPERIENCE

BRISTOL-MYERS SQUIBB, Wallingford, CT 9/1991- 3/2011

Associate Research Scientist II Hepatitis (2004 - 2011)

Designed, performed and analyzed experiments to find and characterize drug-like compounds as potential viral inhibitors of Hepatitis C.

Used cell culture techniques for multiple drug screening, developed assays and used new technologies to address drug induced cytotoxicities.

Combination experiments performed in collaboration with biostatistics and became responsible for the advancement of inhibitors to clinical studies.

Characterization of inhibitors and mapping of resistance were used to direct the program. Used cell based screening for resistance, for target validation, and potential screens to address drug related cell toxicity or needed morphological changes of the inhibitors. Performed human serum binding assays.

Molecular biology added or subtracted mutations thought important for inhibitor resistance or specificity. Created stable cell lines and tested resistance via transient assays.

Made genotype specific enzymes (WT and mutant HCV) and checked for protein expression. Transformed WT or mutant HCV DNA into E.Coli, grew cultures, induced the cells to produce protein. Checked pre-induced and post-induced production of protein on coommassie gel.

Edited HCV database and consolidated important information by total number of sequences and number of variants by genotype.

Gave presentations regarding progress of the program and analysis of specific data including the implications of current status and what should follow. Kept accurate notebook, paper and electronic to record experiments. Pilot tester of new biological data programs looking for issues or incompatibility. Was part of company emergency medical team.

Associate Research Scientist I and II RSV,

Influenza A, B, C, Bovine RSV, Parainfluenza 3 (1997 – 2004)

Characterized potential inhibitors against viruses and performed mechanism of action studies using Pulse-Chase experiments, and GFP labeled proteins.

Created drug-specific viral mutants via cell culture adaptation as well as cloning.

Mapped the amino acid changes found in specific mutant strain sequence.

Cloned site-specific viral mutants sequenced and tested in transient assay.

Propagated and specificity tested a series of RSV Clinical Isolates.

Propagated, frozen and expanded multiple cell lines.

Screened for inhibitors using a variety of viruses and cell lines.

Made and purified enzymes for invitro compound testing using Baculovirus and E.Coli.

Cytomegalovirus (HCMV), Herpes Simplex 1 (HSV1), Rotavirus, Human Immunodeficiency Virus (HIV) (1994-1997)

Propagated HCMV and HSV1 in cell culture to look at the inhibition of viral DNA polymerase by Lobucavir.

Developed a cell based assay for Rotavirus

Validated a strand transfer assay for HIV

Supervisor, Media Preparation Laboratory (1993 – 1994)

Supervised three direct reports, 2 Media Prep Technicians and 1 Glass Wash Technician.

Prepared yearly evaluation reviews of direct reports.

Organized all day to day activities including media preparation, ordering, troubleshooting and record keeping.

Media Preparation Laboratory Group Leader (1991 – 1993)

Developed a new Media Preparation Laboratory for the BMS Wallingford site.

Ordered and maintained equipment and stock.

Hired and supervised two Media Preparation Technicians and a Glassware Technician.

Interacted with researchers to earn their trust and accommodate their media usage.

Prepared daily schedule, met troubleshooting needs and budgetary concerns.

Farmington Center for Reproduction, Farmington, CT 2/1990 – 9/1991

Office Manager, Medical Assistant, Laboratory Technician

Scheduled patients for office appointments and surgeries. Assisted with procedures, performed blood pressure, and venipuncture.

Updated patient charts with surgical notes or blood work results. Billed patients’ insurance and gathered all necessary information for them regarding claims. Received and posted payments to patient’s accounts and prepared the daily deposit.

Ran quantitative electromagnetic immunoassays for multiple hormone levels including HCG tests (pregnancy tests).

American Red Cross, Farmington, CT 9/1988 – 2/1990

Blood Components Laboratory Assistant

Produced, labeled and shipped blood components.

Have been Temporary Supervisor.

Attending school 5/1988- 9/1988

Saint Joseph College, West Hartford, Ct 06117 9/1987 – 5/1988

Laboratory Assistant

Made chemical solutions, broths and agars for students.

Transferred, isolated and identified cultures from clinical samples.

EDUCATION

Bachelor of Science in Biology

University of Saint Joseph, West Hartford, Ct – worked part time to full time while earning degree-1992

ABSTRACTS, REPORTS & PUBLICATIONS

(Some abstracts and reports are proprietary.)

Internal Reports

• Co-author to multiple documents to the FDA and internal proprietary reports.

Abstracts

• Lobucavir: A Potent Inhibitor of Human Cytomegalovirus DNA Polymerase. D. J. Tenney, S. M. Voss, C. W. Cianci, R. K. Hamatake, M. Alam, and A. K. Sheaffer. Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Ct, 06492. 19976th International Cytomegalovirus Workshop, Perdido Beach Resort, Orange Beach, Alabama, U.S.A. March 5-9.

• HCV NS5A inhibitor: from screen hit to clinic. Gao, M., Fridell, R., O’Boyle, D., Qui, D., Sun, J.H., Lemm, J., Nower, P., Valera, L., Voss, S., Liu, M., Belema, M., Nguyen, V., Romine, J.L., Martin, S.W., St. Laurent, D.,Serrano-Wu, M., Snyder, L.B., Colonno, R.J., Hamann, L.G., Meanwell, N.A., 2008. In: 15th International Symposium on Hepatitis C Virus and Related Viruses, 2008, San Antonio, TX, USA (Abstract89).

• In Vitro Activity of the Combination of Pegylated Interferon-Lambda (PEG-IFN-? with Direct-Acting Antivirals in the HCV Replicon Model (ID # 898811), The Liver Meeting AASLD, Oct 29-Nov 2., Boston, Mass. 2010

• Genotypic and Phenotypic analysis of HCV NS5A Inhibitor Resistance Variants: Correlations Between In vitro and In vivo Observations (ID # 899104), The Liver Meeting AASLD, Oct 29-Nov 2., Boston, Mass. 2010

• Synthesis and SAR Studies on Novel Heteroaryl Fused Tetracyclic Indole-Diamide Compounds: Potent Allosteric Inhibitors of the Hepatitis C Virus NS5B Polymerase Enzyme. Min Ding, Feng He, Xiaofan Zheng, Thomas W Hudyma, Michael A Poss, John F Kadow, Karen L Rigat, Ying-Kai Wang, Robert Fridell, Julie Lemm, Dike Qiu, Mengping Liu, Stacey Voss, Min Gao, Susan B Roberts and Robert G Gentles. the 240th ACS National meeting, Boston, MA, August 22-26, 2010

• Synthesis and SAR Studies on Highly Potent, Novel, N,1-C2- Phenyl-Bridged 2-Phenyl-Indole-6-Carboxamide Based Hepatitis C Virus NS5B Inhibitors, Xiaofan Zheng*, Thomas W.Hudyma, Min Ding, Feng He, Michael A. Poss, John F. Kadow, Chong-Hwan Chang, John Wan, Mark R. Witmer, Paul Morin, Daniel M. Camac, Steven Sheriff, Brett R. Beno, Karen L. Rigat, Ying-Kai Wang, Robert Fridell, Julie Lemm, Dike Qiu, Mengping Liu, Stacey Voss, Susan B. Roberts, Min Gao, Jay Knipe and Robert G. Gentles, the 240th ACS National meeting, Boston, MA, August 22-26, 2010, MEDI 126

• Combination of pegylated interferon lambda (PEG-IFN-λ) with direct-acting antivirals shows promise in HCV preclinical studies. Jacques Friborg1, Amy Sheaffer1, Jeremy. A. Freeman2 Susan Chaniewski1, Steven Levine1, Chaoqun Chen1, Stacey Voss1, Julie Lemm1, Min Gao1, Antara Majumdar1 Dennis M Miller2 & Fiona McPhee1, Bristol-Myers Squibb, Wallingford, CT and Zymogenetics Inc, Seattle, WA. AASLD 2010

• IN VITRO DAA COMBINATION STUDIES TO ADDRESS HCV CLINICAL FINDINGS, Authors: Lemm J A1, Liu M1, Voss S1, Gao M1, EASL meeting 2011.

• In Vitro Comparative Analysis Between IFN-Lambda and IFN-Alpha During Combination Treatment With Direct-Acting Antivirals Targeting Hepatitis C Virus. Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Lemm JA, Voss S, Gao M, McPhee

Bristol-Myers Squibb, Research and Development, Wallingford, CT

Publications

• Lobucavir Is Phosphorylated in Human Cytomegalovirus-Infected and –Uninfected Cells and Inhibits the Viral DNA Polymerase. Antimicrobial Agents and Chemotherapy, Vol.41. (1997) No.12:2680-2685.

• Identification of Two Inhibitors of Respiratory Syncytial Virus Entry with Distinct Modes of Action. Cianci C, Kadow K, Voss S, Colonno R and Krystal M. 2003Manuscript unpublished.

• Orally Active Fusion Inhibitor of Respiratory Syncytial Virus. Antimicrobial Agents and Chemotherapy, Vol.48.(2004) No.2:413-422.

• HCV NS5A Inhibitor: From Screen Hit to Clinic.(2008)

• Corrigendum to “Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamines to the hepatitis C virus polymerase” [Bioorg. Med. Chem.Lett.21 (2011) 2212]

• Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: Potent allosteric inhibitors of the hepatitis C virus NS5B polymerase. Received 6 January 2012. Accepted 21 February 2012. Available online 1 March 2012. [Bioorg. Med. Chem.Lett.]

• Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase. Accepted 2 March 2011. Available online 6 March 2011. [Bioorg. Med. Chem.Lett.]

• Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus. Received 11 January 2011. Accepted 17 March 2011. Available online 23 March 2011. . [Bioorg. Med. Chem.Lett.]

• Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor Daclatasvir. Lenore Pelosi, Stacey Voss, Mengping Liu, Min Gao, and Julie Lemm, accepted by Antimicrobial Agents and Chemotherapy. July 2012.

Patents

• Combinations of Hepatitis C Virus Inhibitors. The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations. Current U.S. Classification: 424/85.7; 424/85.4; 514/43; 514/309

• Combinations of Hepatitis C Virus Inhibitors. The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations. Pub. No: WO/2012/018829; International Application No: PCT/US2011/046285. International filing date 02.08.2011. Publication date 09.02.2012. IPC: A61K 9/00 (2006.01)

• Combinations of a specific HCV NS5A Inhibitor and an HCV NS3 Protease Inhibitor. Pub. No: WO/2011/046811; International Application No: PCT/US2010/051898. International filing date 8.10.2010. Publication date 21.04.2011. IPC: A61K 38/06 (2006.01), A61K 31/4178 (2006.01), A61K 45/06 (2006.01), A61P 31/12 (2006.01)

Contact this candidate